Benzinga | Feb 17, 2021 09:04AM EST

Adamis Pharmaceuticals Says Received Notice That One Patent Application Relating To ZIMHI Was Allowed By U.S. Patent And Trademark Office

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHI(tm) high dose naloxone injection product candidate, intended for the treatment of opioid overdose, was allowed by the U.S. Patent and Trademark Office. The allowed claims describe a naloxone composition at a dose greater than or equal to five milligrams configured for administration as an injection. The company believes this patent should protect and strengthen the existing intellectual property associated with the product candidate.